BioNTech SE (VIE:BNTX)

Austria · Delayed Price · Currency is EUR

82.85

-3.85 (-4.44%)

At close: Oct 8, 2026

BioNTech SE Employees

BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.

Employees

7,807

Change (1Y)

1,035

Growth (1Y)

15.28%

Revenue / Employee

€339,439

Profits / Employee

€216,011

Market Cap

20.65B

Employees Chart

Employees History

Date	Employees	Change (1Y)	Growth (1Y)
Dec 31, 2025	7,807	1,035	15.28%
Dec 31, 2024	6,772	639	10.42%
Dec 31, 2023	6,133	1,603	35.39%
Dec 31, 2022	4,530	1,448	46.98%
Dec 31, 2021	3,082	1,141	58.78%
Dec 31, 2020	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro

Related Stocks

Company Name	Employees
Strabag SE	80,923
Erste Group Bank AG	55,231
Voestalpine AG	48,641
Raiffeisen Bank International AG	41,704
Vienna Insurance Group AG	33,636
Andritz AG	30,557
Telekom Austria AG	16,616
OMV Aktiengesellschaft	15,936

Employee Rankings

BioNTech SE News

1 hour ago - BioNTech price target lowered to $114 from $122 at BofA - TheFly
10 days ago - BioNTech to shutter sites in Germany, Singapore as no buyers emerge - Reuters
25 days ago - BioNTech says lung cancer drug candidate prolonged lives in trial - Reuters
25 days ago - BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients - GlobeNewsWire
5 weeks ago - BioNTech to terminate mid-stage trial of mRNA cancer vaccine - Reuters
6 weeks ago - US FDA approves updated COVID vaccines for 2026-27 season - Reuters
6 weeks ago - Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine - Business Wire
7 weeks ago - BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 - GlobeNewsWire